Previous Article | Next Article 
Infection and Immunity, March 2001, p. 1821-1831, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1821-1831.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Detection of Mycobacterium tuberculosis Group
Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR:
Prevalence in Diseased Synovial Tissue Suggests Lack of
Specific Association with Rheumatoid Arthritis
Karen E.
Kempsell,1,*
Charles J.
Cox,2
Andrew A.
McColm,1
Julie A.
Bagshaw,1
Richard
Reece,3
Douglas J.
Veale,3
Paul
Emery,3
John D.
Isaacs,3
J. S. Hill
Gaston,2 and
J. Scott
Crowe1
Glaxo Wellcome Medicines Research Centre,
Stevenage, Hertfordshire SG2 1NY,1
Department of Medicine, University of Cambridge School of
Clinical Medicine, Addenbrookes Hospital, Cambridge CB2
2QQ,2 and Department of Molecular
Medicine, St. James University Hospital, University of Leeds, Leeds LS9
7TF,3 United Kingdom
Received 27 July 2000/Returned for modification 9 October
2000/Accepted 8 December 2000
 |
ABSTRACT |
Infection with mycobacterial species, including Mycobacterium
tuberculosis, has long been implicated in the etiopathology of
rheumatoid arthritis (RA) on the basis of clinical and pathological similarities between tuberculosis and RA. Despite evidence of immune
responses to mycobacterial antigens in RA patient synovial fluid,
cross-reactivity between these and host joint antigens, and the
presence of M. tuberculosis protein antigen in RA synovial fluid, a definite causal association with RA has not been shown. Previous studies from our laboratory using reverse transcriptase PCR
(RT-PCR) of bacterial rRNAs have shown RA synovium to be colonized by a
diverse range of bacteria, most of commensal origin. However, M. tuberculosis group organism (MTG) RNA sequences were found in one
RA patient tissue. Since this was considered of sufficient interest to
warrant further investigation, we devised a M. tuberculosis-specific nested RT-PCR test which could be used for
detection of MTG in a mixed pool of bacterial crDNAs. This test was
used to investigate the distribution of MTG in RA synovial tissue and
also non-RA arthritis and healthy control tissues and was also used to
examine the tissue distribution of MTG in an acute and chronic model of M. tuberculosis infection in the BALB/c mouse. MTG
sequences were found in a high proportion of RA patient synovial
tissues but also in non-RA arthritis control tissues at lower
frequency. This likely reflects trafficking of persistent M. bovis BCG to inflamed joint tissue, irrespective of cause. MTG
were not found in healthy synovial tissue or the tissue of patients
with undifferentiated arthritis. In both the acute and chronic models
of infection in BALB/c mice, M. tuberculosis was also found
to have trafficked to joint tissues, however, no signs of inflammation,
arthritis, or pathology associated with M. tuberculosis
infection was seen. These combined results would argue against a
specific causal role of MTG in RA-like arthritis; however, their role
as adjuvant in immune dysfunction in an innately susceptible host
cannot be excluded.
 |
INTRODUCTION |
Rheumatoid arthritis (RA) is a
complex, multifactorial disease in which innate susceptibility factors
play a substantial role (36). However, heritable factors
can account for only part of disease susceptibility, and onset of RA
has long been thought to be triggered by exposure to some environmental
agent. Prime candidates for this role are bacterial infectious agents,
and great interest has been taken over the years in their possible role
in disease onset (3, 6, 32). Their causative link with
inflammatory arthritis is controversial, as early studies which sought
to establish an association between disease pathology and the diverse
range of bacterial species which have been isolated from diseased
joints, using conventional culture methods, were unable to do so
(22, 62). A number of different studies identified in RA
joint material a variety of bacterial species which could not be
directly associated with disease pathology, thus negating a simple,
single-pathogen role for involvement of bacteria in RA. However,
inflammatory arthritis can be elicited by infection with a variety of
bacterial and viral species in animal models (19), and it
is possible that more than one organism is involved in human disease,
especially given the heterogeneous nature of RA and the variation in
disease severity between individuals.
With the advent of more sensitive molecular techniques for the
detection of bacteria in disease tissue (50), interest has again been revived in investigating the possibility of an infectious etiology for RA. Work from our laboratory has shown the presence of
possibly live bacteria in the joints of patients with a variety of
different arthropathies, using reverse transcriptase PCR (RT-PCR) for
amplification of bacterial rRNAs (28). Detailed sequencing analyses of the amplified products has shown the picture to be considerably more complex that was once thought, with the detection of
multiple bacterial species in each patient. These studies have been
supported by those from Wilbrink and coworkers (66) and other groups (68), who have also shown that synovial
tissue and fluid from patients with a number of different types of
arthritis contain bacterial nucleic acids, sequence analyses again
showing the presence of multiple organisms. Similar studies have also shown the presence of bacterial polysaccharide antigen
(41) in RA synovial tissue and unidentified bacillus-like
organisms in RA synovial explant cultures (39). Thus,
evidence of live bacteria and of their nucleic acids and antigens have
been found in RA synovial tissue and fluid, all of which could
contribute to disease pathology. Whether bacteria and their products
are instrumental in the onset or chronicity of RA remains unknown, but
these studies would certainly suggest that arthritis joint material is
not sterile, as thought previously.
The presence of multiple bacterial species in the tissues of patients
with RA, but also patients with other arthropathies, has called into
question the involvement of these organisms in the underlying
pathological processes and has implied general colonization as a
consequence of the compromise of chronically diseased and inflamed
tissue (28). Many of the bacterial species detected were
commensal organisms with low pathogenic potential, which presumably had
trafficked from other body sites. Very few organisms of known
pathogenic potential other than opportunistic pathogens, e.g.,
Staphylococcus epidermidis, were detected. However, in one
RA patient we detected the presence of crDNA sequences from
Mycobacterium tuberculosis group organisms (MTG) at low
frequency, 2 of 48 clones sequenced in a mixed pool of bacterial crDNAs
(4%). In addition to our own studies where we have detected a
number of mycobacterial species in patients with arthritis including MTG, Wilbrink and coworkers have uncovered evidence of other
mycobacteria in the synovial fluid of RA patients by mycobacterial
species-specific nested PCR (63). Similar studies by Wu
and coworkers have uncovered evidence of M. tuberculosis
protein antigen in RA synovial fluid (69, 70). Thus, RA
synovial tissue and fluid in addition to the other organisms identified
contain mycobacterial species, some of which, e.g., MTG, have known
pathogenic potential.
The detection of MTG was therefore thought to be of sufficient interest
to warrant further investigation, as mycobacteria in general and
M. tuberculosis in particular have long been postulated to
be involved in the etiopathogenesis of RA on the basis of clinical and
pathological similarities with tuberculosis (27, 34, 55, 56). However, previous studies to investigate the possible
presence of mycobacteria including MTG by PCR for genomic DNA
had been unsuccessful (24, 48). We thought that these
negative results may have been due to low abundance of target bacterial
DNA sequences, as we had also found certain bacterial sequences
including MTG at low frequency.
From our previous studies, we proposed that RT-PCR of bacterial RNA is
more sensitive than PCR of bacterial genomic DNA in the
detection of bacterial nucleic acids in disease tissue. Enhanced detection of species-specific sequences at low abundance in a mixed
pool can be facilitated by combination of universal RT-PCR and
species-specific nested PCR. This has been used previously to great
effect in the detection of Yersinia spp. in a patient with
known Yersinia-mediated reactive arthritis (ReA)
(18). We therefore used this adaptation of RT-PCR using
universal oligonucleotide primers to bacterial rRNA and MTG
species-specific, nested primers to investigate the prevalence of this
group of organisms in the synovial tissue of three cohorts of patients
with late- and early-stage RA or other forms of arthritis and in
healthy controls. These studies have shown MTG organisms to be present
in the tissues of patients with a number of different arthritides;
however, although there appears to be trafficking of these organisms to
inflamed joint tissue, there is no apparent specific association with RA.
We also used this technique to follow the in vivo tissue location of
MTG in an acute and chronic model of M. tuberculosis infection in the BALB/c mouse to ascertain whether MTG are able to
traffic to tissues other than those which exhibit signs of overt
M. tuberculosis disease. MTG were found to have trafficked to joint tissue both in an acute and a chronic model of M. tuberculosis infection. However, the presence of M. tuberculosis in joint tissue did not appear to lead to
inflammation or the development of arthritis disease pathology in this
mouse model, perhaps implying no ability of this organism to cause
disease in these tissues. These combined results would suggest that the
presence of MTG in human and mouse joint tissue does not appear to be
of significance in the primary etiopathology of inflammatory arthritis,
although their role as adjuvant in the potentiation of immune
dysfunction in RA cannot be excluded.
 |
MATERIALS AND METHODS |
Materials.
All general chemicals were purchased from
Sigma-Aldrich Co. Ltd., Poole, Dorset, England. Media constituents were
provided by Oxoid Ltd., Basingstoke, Hampshire, England. A Hybaid
Ribolyser kit was purchased from Hybaid Teddington, Middlesex, England. Amplitaq Taq polymerase and buffers were supplied by
Perkin-Elmer, Warrington, Cheshire, England. Superscript II reverse
transcriptase and all oligonucleotide primers were purchased from
GibcoBRL Life Technologies, Paisley, Scotland. Deoxyribonucleosides
were purchased from Roche Diagnostics, Lewes, Sussex, England.
Growth of mycobacterial species and isolation of mycobacterial
DNA.
All mycobacterial strains (Table
1) were grown on Dubos medium plus
supplements (16) with the exception of M. smegmatis, which was grown on Lab-Lemco broth (pH 7.4) containing
0.3% (wt/vol) Lab-Lemco powder and 0.5% (wt/vol) peptone (Oxoid).
These were incubated at 37°C, without shaking, for 7 to 21 days,
according to the growth rate of the species. DNA was extracted from
washed mycobacterial cell pellets recovered by centrifugation, using the guanidinium hydrochloride extraction method (25),
according to the published procedure. After recovery by ethanol
precipitation, mycobacterial DNA pellets were dried and then dissolved
in Tris-Cl buffer containing 0.1 mM EDTA prior to use.
Acute and chronic M. tuberculosis infection models of
BALB/c mice.
To ascertain (i) the potential of M. tuberculosis to traffic to joint tissue and (ii) the technical
feasibility of MTG-specific PCR to detect live organisms in infected
tissue samples, a BALB/c mouse model of acute and chronic M. tuberculosis infection was established. Tissues from infected mice
were then assayed for the presence of MTG by nested, specific RT-PCR
and also by conventional bacteriological staining. Female BALB/c mice
(weighing approximately 20 g, Charles River) were maintained in
isolators under ACDP category 3 conditions. These were infected
intravenously with 200-µl volumes of M. tuberculosis
(H37Rv) which had been prepared to the appropriate dilution (Table
2) from stocks stored at
80°C. To
achieve a long-term (118-day) chronic infection a challenge
concentration of approximately 4 × 104 CFU was
administered to each mouse. To establish a more acute infection, we
used a higher challenge level (approximately 5 × 106
CFU) for which the survival time was between 28 and 40 days. Mice with
either chronic (day 118) or acute (28-day) infections were sacrificed
by cervical dislocation; tissues were then removed aseptically for
RT-PCR and histological analyses. After debridement of external tissue
from excised joints, all tissues were either (i) processed for RNA
extraction by being placed immediately into 500 µl of guanidinium
isothiocyanate extraction buffer (GIEB) medium and then stored at
80°C or (ii) fixed in 10% neutral buffered formalin for
histological evaluation. After fixation, the joints were decalcified in
EDTA, processed to paraffin, sectioned at 4 µm, and stained with
hematoxylin and eosin or Ziehl-Neelson acid fuschin. All samples were
examined microscopically using a Leica DM Research microscope and were
scored for inflammation, granuloma formation, and the presence of
acid-fast bacteria. A total of 11 joints from five chronically infected
mice and 13 joints from five acutely infected mice were collected along
with uninfected joints, eight control joints from three uninfected mice. In addition, lung and spleen tissues from one uninfected and one
acutely infected mouse were removed for use as positive controls (Table
2).
Tissue handling and RNA isolation.
RA, osteoarthritis (OA),
and other disease (undifferentiated arthritis [UA]) synovial tissue
specimens were collected with patient consent at surgery for joint
replacement with a few exceptions: in cohort 1, the RA patient 2 specimen, which was obtained by needle biopsy, and OA patient 20 specimen, which was tissue removed at first metatarsal phalangeal
surgery. Healthy synovial tissues were collected from patients 22 and
23 by needle biopsy and from patient 21 at arthroscopy for unexplained
knee pain, (clinical details of patients in cohort 1 are given in Table
3). Healthy controls were not age and sex
matched to the RA patient group; however, the trauma specimens were
unlikely to have features of joint disease pathology in common with
arthritis patients of many years duration. Full microbiological
analyses of patients from cohort 1 have been published in detail
elsewhere (28). Synovial tissue was obtained in cohort 2 patients with from late-stage RA and OA, plus patient controls with
arthritis due to other causes (Table 4),
either at surgery for joint replacement, from power tool washings for
debridement of inflamed synovium, or by arthroscopic biopsy. Conditions
of all late-stage RA patients according to the American College of
Rheumatology criteria (5) were classified as late-stage
disease, i.e., disease of many year's duration with joint destruction
requiring arthroplasty. Synovial tissues from patients in cohort 3 (Table 5) with early RA or reactive
arthritis (ReA), i.e., categorized as having disease of less than 1 year's duration, were obtained with permission by needle biopsy.
Resected synovial tissue samples collected at surgery were immediately
frozen on dry ice and then stored at

80°C prior to
use. Total RNA
was isolated from late- and early-stage RA, OA,
and ReA synovial tissue
and from control and mouse tissues using
a modification of the Hybaid
RiboLyser, guanidinium isothiocyanate-acid
phenol extraction method, in
which buffer A was substituted with
fresh GIEB (
38). In
short, approximately 0.1 g of tissue was
thawed in 500 µl of
GIEB, chopped finely (mouse joint material
excepted, due to the high
bone content), and then extracted by
shear lysis in the presence of 500 µl of phenol (pH 4.0) and 100
µl of chloroform isoamyl alcohol in a
Hybaid Ribolyser, according
to the manufacturer's instructions. Total
RNA was recovered by
precipitation with 2-propanol, dried, and then
dissolved in diethyl
pyrocarbonate-treated water containing 0.1 mM
EDTA. Bacterial
RNAs were recovered from washed
Escherichia
coli and
M. tuberculosis cell pellets, using the same
protocol with minor modifications
based on the protocol of Mangan and
coworkers, i.e., Divolab (pH
4.0) added to 1% to GIEB prior to shear
lysis (
37).
Specific detection of MTG by rDNA-specific PCR of mycobacterial
DNAs.
rDNA fragments were amplified from mycobacterial
genomic DNAs by PCR amplification using universal, bacterial
rRNA-specific oligonucleotide primers R1 and R2 (i.e., PCR1; all
oligonucleotide sequences are given in Table
6). Genomic DNA (5 fg) was used as template in a PCR mix containing 1× Amplitaq PCR buffer, 0.2 µM
deoxynucleoside triphosphates (dNTPs), 0.2 µM PCR primers R1 and R2,
1.5 mM MgCl2, and 2.5 U of Amplitaq Taq
polymerase. Amplication was performed as follows: 94°C for 4 min,
followed by 30 cycles of 58°C for 1 min, 72°C for 3 min, and 94°C
for 1 min. MTG-specific nested PCR (PCR2) was then performed on
amplified bacterial rDNA fragments by the following means. One
microliter of the PCR1 product was used as the template in a PCR mix
containing 1 × Amplitaq PCR buffer, 0.2 µM dNTPs, 0.2 µM PCR
primers TB1 and TB2, 1.5 mM MgCl2 and 2.5 U of Amplitaq
Taq polymerase. The amplification program consisted of
94°C for 4 min, followed by 30 cycles of 72°C for 3 min and 94°C
for 1 min. All PCR products were visualized by electrophoresis on a 2%
agarose gel.
Amplification of bacterial crDNAs and M. tuberculosis-specific nested PCR of mouse and human tissue RNA by
Reverse T-PCR.
Arthritis and control tissue and bacterial RNAs
were reverse transcribed by the same method in 4 µl of buffer
containing 50 mM Tris-Cl (pH 8.3), 75 mM KCl, 3 mM MgCl2,
40 µM dNTPs, approximately 25 to 100 ng of RNA, and 20 µM primer
R2. This mixture was heated to 65°C for 1 min and then cooled to room
temperature for 3 min; 200 U of Superscript reverse transcriptase was
added, and the mix was incubated at 37°C for 1 h. The reaction
was stopped by incubation at 65°C for 10 min. General bacterial
ribosomal crDNA fragments were amplified from total cDNA by the
procedure outlined above for PCR1 of DNA templates; MTG-specific nested
PCR2 was then performed on RNA-derived, PCR1-amplified crDNA fragments as outlined above. Amplified MTG-specific products from human tissue
samples and bacterial RNAs were confirmed, either by Southern blotting
using established techniques (38) and hybridization using
32P-labeled, gel-purified M. tuberculosis-specific PCR2 fragment or by gel purification and sequencing.
 |
RESULTS |
Specific detection of MTG from closely related bacteria by nested
PCR.
MTG could be distinguished from closely related bacteria (a
total of 25 other species and substrains) by nested PCR using primers
R1 and R2 in a primary mix (PCR1) and primers TB1 and TB2 in a
subsequent nested reaction (PCR2) (Fig.
1). PCR1 amplified fragments of the same
size from all bacterial DNAs tested, as expected (primers R1 and R2 are
generic and will amplifiy rDNA fragments from most bacterial species
[Fig. 1a]). However, PCR2 amplified only a band of approximately 150 bp in MTG, M. tuberculosis subsp. H37Rv (virulent type
strain), M. tuberculosis H37 Ra (avirulent strain), M. bovis BCG (vaccine strain), and M. microti (vole
bacillus) (Fig. 1b). Under less stringent annealing conditions (less
than 70°C), PCR2 weakly amplifies fragments of similar size in
strains of M. marinum (data not shown); however, under the
stringent PCR conditions used (annealing temperature of 72°C),
PCR2 is MTG specific.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Results of PCR1 using 5 fg of bacterial genomic
DNA as template (a) and MTG-specific nested PCR 2 using 1 µl of PCR1
product as template (b).
|
|
To establish the efficacy of the nested MTG-specific PCR test on
bacterial crDNAs, 50-ng aliquots of
E. coli or
M. tuberculosis total RNAs were reverse transcribed as described
below, and PCR1
and PCR2 were carried out using 10 fg of
E. coli DNA as control
(Fig.
2). Gel electrophoresis showed a band for
PCR 1 (Fig.
2a)
in all samples as expected (in sample 2, due to trace
amounts
of contaminating DNA) but a band of the appropriate size for
PCR2
only in the
M. tuberculosis RNA sample (Fig.
2b).
Southern blotting
using
32P-labeled, gel-purified
M. tuberculosis PCR2 product confirmed
these observations.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Results of PCR1 (a) and PCR2 (b) on whole bacterial RNAs
lanes: 1, 10 fg of E. coli DNA; 2, 50 ng of E. coli total RNA, no reverse transcription; 3, 50 ng of E. coli RNA reverse transcribed to cDNA; 4, 50 ng of M. tuberculosis total RNA, reverse transcribed to cDNA. Amplification
products from PCR1 and PCR2 were visualized on a 2.0% agarose gel,
transferred to nylon membranes using standard techniques, and then
hybridized with 32P-labeled MTG-specific PCR2 amplification
product using M. tuberculosis genomic DNA as
template.
|
|
Use of specific nested RT-PCR for detection of MTG in M. tuberculosis-infected mouse tissues.
PCR1 and PCR2 were
conducted on joint and control mouse tissues recovered from either
chronically or acutely infected BALB/c mice and controls (Fig.
3). Seven of the mouse tissues from the M. tuberculosis chronically infected mice and control mouse
1 were positive for bacteria using PCR1 (Fig. 3a). Two of these tissues
from infected mice were additionally positive for MTG using specific
nested PCR2 (Fig. 3b); these were both wrist joints (tissues 3a and
7a). These results indicate that M. tuberculosis administered intravenously at low dose can traffic to the joints of
infected BALB/c mice and can be detected using MTG-specific nested
RT-PCR. Interestingly, the results also suggest some low-grade non-M. tuberculosis infection in the remaining PCR1 positive
joints; these were again all wrist joints.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Results of PCR1 and PCR2 on reverse-transcribed mouse
tissue RNAs from M. tuberculosis-infected BALB/c mice and
controls (see Table 2 for tissue details). (a) PCR1; (b) MTG-specific
PCR2.
|
|
In acutely infected animals, tissues from all control and test animals
(with the exception of tissue 8e, hip joint from control
mouse 8), were
positive for bacteria using PCR1 (8c, 9d, 10a,
11c, and 13b were weakly
positive). All tissues from the
M. tuberculosis-infected
mice (except 11c) were additionally positive for MTG using PCR2,
while
the control tissues were not. The control mice in both groups
showed
some signs of laboratory-derived bacterial infection and
pneumonitis,
which would perhaps explain the positive signal obtained
in tissues
from these mice using
PCR1.
Thus,
M. tuberculosis given intravenously at low and high
doses appears to traffic to body tissues in addition to those which
show clear evidence of disease pathology, e.g., lung and spleen
(data
not shown). However, all chronically and acutely infected
animals with
evidence of MTG in joint tissue showed no overt signs
of joint
inflammation. Parallel joints taken from chronically
infected animals
showed no evidence of pathology associated with
M. tuberculosis infection, such as granuloma formation, or any
gross
histopathological evidence of joint damage; some infected
joints showed
evidence of minor damage to the cartilage surface
compared with control
joints (Fig.
4). Thus, despite the
presence
of live organisms in a number of mouse joint tissues in this
animal
model, there appear to be no overt signs of pathology associated
with
M. tuberculosis infection, joint inflammation, or
arthritis.

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 4.
Sections of mouse joints stained with hemotoxylin and
eosin. (a) Wrist joint from uninfected mouse 1; (b) wrist joint from
M. tuberculosis-infected mouse 3. Arrow indicates area
of cartilage disruption in M. tuberculosis-infected mouse
joint.
|
|
Detection of MTG in human arthritis tissue from patient cohorts 1 and 2 by Specific, Nested RT-PCR.
Synovial tissue RNAs of patients
from cohorts 1 and 2 were reverse transcribed and subjected to analysis
for bacteria and the presence of MTG using PCR1 and PCR2 (Fig.
5 and 6 and
Table 7). PCR1 showed the presence of
bacterial rRNA in many of the joint tissues of patients in both study
groups (complete analysis of the bacterial species present in the
joints of patients from cohort 1 has been published in detail elsewhere
[28]).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Result of PCR1 and PCR2 on reverse-transcribed synovial
RNAs from cohort 1 patients (see Table 3 for tissue details). (a) PCR1;
(b) MTG-specific PCR2; (c) Southern blot analysis of PCR2 amplification
products probed with 32P-labeled MTG-specific PCR2
amplification product using M. tuberculosis genomic
DNA as template.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 6.
Result of PCR1 and PCR2 on reverse-transcribed synovial
RNAs from cohort 2 patients (see Table 4 for tissue details). (a) PCR1;
(b) MTG-specific PCR2; (c) Southern blot analysis of PCR2 amplification
products probed with 32P-labeled MTG-specific PCR2
amplification product using M. tuberculosis genomic
DNA as template.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 7.
Summary of results of PCR1 and nested MTG-specific PCR2
on patient tissues RNAs from cohorts 1, 2, and 3
|
|
Initial early analyses using PCR2 to detect the presence of MTG in the
tissue of cohort 1 patients revealed evidence of these
organisms in the
joints of four of nine RA patients (44.4%) and
one of seven OA
patients (14.3%), with none in the UA or control
subjects (Fig.
5b and
Table
7). This result suggested a more
specific association of MTG with
RA inflammatory arthritis compared
with the other groups, particularly
the OA group. However, due
to the small sample size of patients in each
of the study groups,
the significance of the results could not be fully
ascertained.
PCR1 and PCR2 were therefore reapplied to tissue RNAs from
a larger
study group, cohort 2. The results showed the presence of MTG
sequences in a number of patient tissues (Fig.
6b and Table
7),
including 12 of 17 RA samples (70.6%), 8 of 17 OA specimens (47%),
and one each of suspected septic arthritis and psoriatic arthritis
controls. These results suggest no specific association of MTG
sequences with late-stage RA, although their prevalence in this
patient
group appears to be higher. This could be due merely to
the greater
degree of chronic inflammation found in these patients,
leading to a
general increased trafficking of bacteria, perhaps
carried to this area
by immune cells continuously recruited to
the site of
inflammation.
Detection of MTG in synovial tissue from early RA and ReA
patients.
It has been shown previously by our group that
later-stage RA and OA tissues are colonized by a variety of bacteria
and the joint tissues usually contain a number of different species
(28). MTG could be merely a part of this general bacterial
milieu, most likely opportunistically colonizing tissue which is
already diseased and compromised. Therefore, to look for any
association of MTG with early RA, we applied MTG-specific PCR1 and PCR2
to a third cohort of tissues from patients with early-stage RA and ReA
(Fig. 7). The PCR signal generated with
primers R1 and R2 were rather weak, and the products show evidence of
prior nucleic acid degradation. Upon cloning and sequencing, these
products were found to be bacterial in origin (data not shown),
although of short length. However, this does not appear to obviate
their utility as template for nested PCR2, where a clear signal was
generated in a small number of patient samples. Two of six (33.3%) of
the early RA and only one of six (16.67%) of the early ReA patients
were found to have MTG sequences in their synovium (Fig. 7b and Table
7); this implied no specific association of MTG with early RA. In
addition, only a small proportion of early RA patients showed evidence
of MTG in their synovium, perhaps also suggesting no etiopathological link of this group of organisms with disease.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 7.
Result of PCR1 and PCR2 on reverse-transcribed synovial
RNAs from cohort 3 patients (see Table 5 for tissue details). (a) PCR1;
(b) MTG-specific PCR2. PCR2 amplification products were verified by gel
purification and sequence analysis.
|
|
 |
DISCUSSION |
The results presented in this study demonstrate that PCR1 and PCR2
are able to differentiate MTG from closely related bacteria. This
nested-PCR test can be used for detection of MTG in mouse tissues and
also in human synovial tissue from patients with a variety of
arthropathies. In the acute and chronic BALB/c mouse model of
infection, MTG sequences could be detected in tissues which show clear
signs of pathology, e.g., lung and spleen, but were also found in joint
tissue, indicating trafficking of these organisms to peripheral
tissues. The presence of MTG in the joint did not appear to be
associated with signs of pathology associated with M. tuberculosis infection, inflammation, or overt symptoms of
arthritis; however, some minor cartilage damage was observed. These
observations would imply that joint tissue infection with live M. tuberculosis does not lead to RA-like inflammatory arthritis in
this animal model. This result was not unexpected, as no evidence of
M. tuberculosis-associated joint pathology has been found in BALB/c mice, despite years of investigation using this mouse strain as
the host for this infectious organism. To our knowledge, this is the
first report of trafficking of live MTG to mouse joint tissues.
As this study revealed no signs of joint disease in the animals
analyzed, it does not support MTG as etiological agents in inflammatory joint disease in this model. However, the BALB/c mouse may
be an inappropriate strain for these types of studies, as its genetic
background may not confer any susceptibility to RA-like
inflammatory arthritis. In certain rodent strains such as the
Lewis rat, arthritis can be elicited by immunization with heat-killed
M. bovis BCG emulsified in oil (Freund's complete adjuvant)
(7). However, this phenomenon is clearly dependent on the
specific genetic configuration of the model animal, as disease cannot
be initiated by such means in the closely related Fisher (F344) strain.
Freund's complete adjuvant is also commonly used in a number of other
animal models of arthritis (47, 61), without which the
antigen challenge used to elicit joint inflammation is less
effective. Therefore, mycobacteria have strong immunopotentiating properties and in a susceptible host could contribute to immune dysregulation. In susceptible animals and in humans genetically predisposed to inflammatory joint disease, a combination of factors could contribute to disease onset by way of a complex interplay between
infectious agent and host resulting in joint inflammation. For future
studies, it would be of interest to repeat these challenge experiments
in susceptible rodent strains or transgenic for factors conferring
susceptibility to RA such as HLA-DR4.
MTG sequences were found in the synovial tissue of some individuals in
all groups studied with the exception of patients with UA and healthy
controls. The prevalence in late-stage RA synovium was found to be
higher than for the other disease groups, but this may be due in part
to the generally higher degree of inflammation seen in these patients.
However, the observation that MTG are not specifically associated with
the RA group, despite our initial encouraging observations for cohort
1, argues against a simple etiopathological role of these organisms in
late-stage RA. In addition, MTG were not found in all early RA patient
samples, although these results may be influenced by the small size of the biopsy material taken from these patients, which may have contributed to sampling errors. Even taking this fact into
consideration, the relative abundance of MTG in these tissues would
have to be extremely low to be overlooked. Overall, its seems unlikely
that these organisms play a central role in the onset or progression of
inflammatory arthritis, although they may contribute to ongoing inflammatory processes and chronicity, alongside other species in the
general bacterial colonization of synovial tissue. The observation that
the RA group seem to be positive for MTG at a higher frequency
may also perhaps be explained by the fact that RA patients are more
susceptible to bacterial infection in general (57). In
addition, they may also be more susceptible to mycobacterial infection,
as evidenced by case reports of RA patient infection with mycobacterial
species which are usually weakly pathogenic for humans (13, 17,
32) and those which are pathogenic to humans, such as M. tuberculosis (28).
M. tuberculosis is known to cause a number of types of
arthritis in human hosts, including septic arthritis and a form of sterile ReA (Poncet's disease), although these are relatively rare and
the occurence of arthritic manifestations in patients with pulmonary
tuberculosis is generally low (14). This again suggests that in the absence of other contributory factors,
M. tuberculosis infection does not usually
contribute to onset of inflammatory arthritis. However, workers
using antimycobacterial therapies in the treatment of RA (9,
46) have obtained intriguing results, perhaps suggesting from
our studies that elimination of colonizing bacteria can lead to
amelioration of symptoms in some individuals. However, whether these
effects are due to the anti-inflammatory properties of the
antimycobacterials used, or a function of bacterial clearance remains
unknown (28).
Recognition of mycobacterial antigens by synovial T cells and antibody
cross-reactivity between mycobacterial antigens and human proteins
including cartilage components has also been observed in RA patient
synovial fluid and blood (2, 12, 13, 23, 33, 45, 52, 54,
59). However, it is a subject of some controversy as to whether
responses to common bacterial antigens, e.g. heat shock protein 65, are
specific to the mycobacterial homologues or are part of a more
generalized immune reactivity to such proteins by memory cells
recruited to inflammatory lesions (21, 51). However, there
is some evidence that HLA-DR4, one of the susceptibility factors in RA,
may confer increase responsiveness to mycobacterial antigens (44,
45), and as discussed previously mycobacteria and their antigens
appear to have more potent adjuvant properties than those from other
bacterial species. These could contribute to local inflammatory effects
on specific cell types in bone and joint infections. Mycobacterial heat
shock protein 10 has been found to stimulate bone resorption in a bone
explant model, which is proposed to be a contributary factor in
degenerative M. tuberculosis infection of the spine (Potts
disease) (40). Immunization with the same antigen can
modulate adjuvant arthritis in the rat model, suggesting some central
role for this antigen in adjuvant arthritis (49). Other
mycobacterial antigens can also stimulate RA patient-derived
mononuclear cells to cartilage proteoglycan depletion
(67). These observations again suggest that mycobacterial
antigens have strong immunopotentiating properties, which in an
appropriate tissue setting and subject to predisposing conditions
could elicit strong reactivity from resident or infiltrating inflammatory cells. Whether such mechanisms are at play in RA remains a
topic for future study.
Overall, the results presented here provide evidence of a previously
unsuspected presence of MTG in inflamed synovial tissue irrespective of
cause. As this test cannot differentiate between different members of
the MTG complex because their rRNA sequences are 99.9% conserved
(29), these observations most likely reflect persistence
of M. bovis BCG. Most of these these individuals are highly
likely to have received BCG vaccination, and it is unlikely that these
results are due to infection with virulent M. tuberculosis; however, recrudescence of previous M. tuberculosis infection
cannot be excluded. Whatever the origin of these MTG sequences, the
organisms are likely to have been carried to the site of disease by
inflammatory cells, as is probably likely with the many other organisms
found in these diseased tissues (28). M. bovis
BCG is known to persist in vaccinated individuals for long periods of
time, as has been suggested from emerging case reports on individuals
with human immunodeficiency virus who after progression to AIDS succumb
to recrudescent M. bovis BCG infection some considerable
time after receiving vaccination (4, 8, 53, 60, 64).
If latent organisms are present in patients with inflammatory
arthropathies, it is also likely that immunosuppressive therapies used
in the control of inflammatory joint disease could lead to reactivation
and reemergence of these bacilli. However, they may be unconnected to
disease pathology, and their presence may be incidental. Persistence
and colonization of joint tissues could also be contributed to by
deficiencies in host immune surveillance mechanisms leading to impaired
bacterial clearance. This hypothesis is supported by previous
observations that patients with RA often exhibit signs of impairment of
inflammatory cell function. These defects are particularly found
in cells associated with bacterial killing, e.g.,
professional phagocytes and T cells (1, 17, 26, 30, 43,
58, 65), and may be associated with cytokine hyperstimulation as a consequence of the chronic inflammatory nature of
the disease (10, 11). RA patients also show defects in mucosal integrity (42), which could lead to
increased bacterial trafficking from other body sites already
heavily colonized by commensal organisms. Whether these factors
could combine to promote accumulation of opportunistic bacterial
colonizers in diseased tissue from either resident or environmental
sources is unclear. However, these observations may contribute to our
understanding of the complex mechanisms at work in the pathology of
inflammatory arthritis and may also influence our strategy approaches
to patient therapy. Future strategies could employ antibacterial
treatment in conjunction with conventional therapies, which if their
combined effects prove beneficial may provide clues as to the role of
these colonizing bacteria in disease pathology.
 |
ACKNOWLEDGMENTS |
We thank Gabriel Panayi, Dorian Haskard, Peter Sewell, George
Southgate, Gill Pountain, Andrew Hassell, Robin Strachan, Neil Hunt,
and Sally Roberts for the kind provision of clinical material for use
in this work. We also thank Anthony Savage for assistance in analysis
of histological sections.
We thank Glaxo Wellcome UK for sponsoring this project and for
financial support of Charles J. Cox.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Glaxo Wellcome
Medicines Research Centre, Department of Immunopathology, Gunnels Wood Road, Stevenage, Hertfordshire SG1 1NY, United Kingdom. Phone: (44)
1438 764975. Fax: (44) 1438 764818. E-mail:
kek23980{at}GlaxoWellcome.co.uk.
Editor:
W. A. Petri Jr.
 |
REFERENCES |
| 1.
|
Abdou, N. I.,
H. B. Lindsley,
L. S. Racela,
E. Pascual, and K. M. Hassanein.
1981.
Suppressor T cell dysfunction and anti-suppressor cell antibody in active early rheumatoid arthritis.
J. Rheumatol.
8:9-18[Medline].
|
| 2.
|
Aguas, A.,
N. Esaguy,
C. E. Sunkel, and M. T. Silva.
1990.
Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DR beta subsets of major histocompatibility complex class II molecules.
Infect. Immun.
58:1461-1470[Abstract/Free Full Text].
|
| 3.
|
Albani, S., and D. A. Carson.
1996.
A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis.
Immunol. Today
17:466-470[CrossRef][Medline].
|
| 4.
|
Armbruster, C.,
W. Junker,
N. Vetter, and G. Jaksch.
1990.
Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination.
J. Infect. Dis.
162:1216[Medline].
|
| 5.
|
Arnett, F. C.,
S. M. Edworth,
D. A. Bloch,
D. J. Shane,
J. F. Fries, and N. S. Cooper.
1988.
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum.
31:315-324[Medline].
|
| 6.
|
Behar, S. M., and S. A. Porcelli.
1995.
Mechanisms of autoimmune disease induction: the role of the immune response to microbial pathogens.
Arthritis Rheum.
38:458-476[Medline].
|
| 7.
|
Billingham, M. E. J.
1995.
Adjuvant arthritis: the first model, p. 25-46.
In
B. Henderson, J. C. W. Edwards, and E. R. Pettipher (ed.), Mechanisms and models in rheumatoid arthritis. Academic Press Ltd., London, England.
|
| 8.
|
Blondon, H.,
T. Guez,
G. Paul,
C. Truffot-Pernot, and D. Sicard.
1991.
BCG adenitis 6 years after vaccination in AIDS.
Presse Med.
20:1091.
|
| 9.
|
Caruso, I.
1993.
Antituberculous drugs in rheumatoid arthritis.
J. Rheumatol.
20:199-200[Medline].
|
| 10.
|
Cope, A. P.,
M. Londei,
N. Randall Chu,
S. B. A. Cohen,
M. J. Elliot,
F. M. Brennan,
R. N. Maini, and M. Feldmann.
1994.
Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.
J. Clin. Investig.
94:749-760.
|
| 11.
|
Cope, A. P.,
R. S. Liblau,
X.-D. Yang,
M. Conglia,
C. Laudanna,
R. D. Schreiber,
L. Probert,
G. Kollias, and H. O. McDevitt.
1997.
Chronic tumour necrosis factor alters T cell responses by attenuating T cell receptor signalling.
J. Exp. Med.
185:1573-1584[Abstract/Free Full Text].
|
| 12.
|
Crick, F. D., and P. A. Gatenby.
1992.
Limiting-dilution analysis of T cell reactivity to mycobacterial antigens in peripheral blood and synovium from rheumatoid arthritis patients.
Clin. Exp. Immunol.
88:424-429[Medline].
|
| 13.
|
De Graeff-Meeder, E. R.,
M. Voorhorst,
W. van Eden,
H. J. Schuurman,
J. Huber,
D. Barkley,
R. N. Maini,
W. Kuis,
G. T. Rijkers, and B. J. Zegers.
1990.
Antibodies to the mycobacterial 65-kDa heat shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis.
Am. J. Pathol.
137:1013-1017[Abstract].
|
| 14.
|
Dlugovitky, D.,
A. Torres,
M. C. Hourquescos,
M. J. Svetaz,
N. Quagliato,
E. Valentini,
B. Amigot,
O. Molteni, and O. Bottasso.
1995.
Low occurance of arthritic manifestations in patients with pulmonary tuberculosis. T cell subsets and humoral studies.
Mem. Inst. Oswald Cruz (Rio de Janeiro)
90:623-628.
|
| 15.
|
Dreisin, R. B.,
C. Scoggin, and P. T. Davidson.
1976.
The pathogenicity of Mycobacterium fortuitum and Mycobacterium chelonii in man: a report of seven cases.
Tubercle
57:49-57[CrossRef][Medline].
|
| 16.
|
Dubos, R. J., and B. D. Davis.
1946.
Factors affecting the growth of tubercle bacilli in liquid media.
J. Exp. Med.
43:409-423.
|
| 17.
|
Emery, P.,
G. S. Panayi, and A. M. E. Nouri.
1984.
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis.
Clin. Exp. Immunol.
57:123-129[Medline].
|
| 18.
|
Gaston, J. S. H.,
C. Cox, and K. Granfors.
1999.
Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis.
Arthritis Rheum.
42:2239-2242[CrossRef][Medline].
|
| 19.
|
Griffiths, M. M.
1995.
Arthritis induced by bacteria and viruses, p. 411-430.
In
B. Henderson, J. C. W. Edwards, and E. R. Pettipher (ed.), Mechanisms and models in rheumatoid arthritis. Academic Press Ltd., London, England.
|
| 20.
|
Hernandez-Cruz, B.,
M. H. Cardiel,
A. R. Villa, and J. Alcocer-Varela.
1998.
Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study.
J. Rheumatol.
25:1900-1907[Medline].
|
| 21.
|
Hirata, D.,
I. Hirai,
M. Iwamoto,
T. Yoshio,
A. Takeda,
J. I. Masuyama,
A. Mimori,
S. Kano, and S. Minota.
1997.
Preferential binding with Escherichia coli HSP60 of antibodies prevalent in sera from patients with rheumatoid arthritis.
Clin. Immunol. Immunopathol.
82:141-148[CrossRef][Medline].
|
| 22.
|
Hollander, J. L.
1985.
History of rheumatoid arthritis: an American perspective, p. 11-17.
In
P. D. Utsinger, N. J. Zvaifler, and G. E. J. B. Erlich (ed.), Rheumatoid arthritis: etiology: diagnosis: management. Lippincott Co., Philadelphia, Pa.
|
| 23.
|
Holoshitz, J.,
I. Drucker,
A. Yaretzky,
W. van Eden,
A. Klajman,
Z. Lapidot,
A. Frenkel, and I. Cohen.
1986.
T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage.
Lancet
2:305-309[Medline].
|
| 24.
|
Jalal, H.,
M. Millar,
C. Linton, and P. Dieppe.
1994.
Absence of Mycobacterium tuberculosis DNA in synovial fluid from patients with rheumatoid arthritis.
Ann. Rheum. Dis.
53:695-698[Abstract/Free Full Text].
|
| 25.
|
Ji, Y.-E.,
K. E. Kempsell,
M. J. Colston, and R. A. Cox.
1994.
Nucleotide sequences of the spacer-1, spacer-2 and trailer regions of the rrn operons and secondary structures of precursor 23S rRNAs and precursor 5S rRNAs of slow-growing mycobacteria.
Microbiology
140:1763-1773[Abstract/Free Full Text].
|
| 26.
|
Katona, I. M.,
K. Ohura,
J. B. Allen,
L. M. Wahl,
D. E. Chenoweth, and S. M. Wahl.
1991.
Modulation of monocyte chemotactic function in inflammatory lesions. Role of inflammatory mediators.
J. Immunol.
146:708-714[Abstract].
|
| 27.
|
Keat, A.
1993.
TB or not TB?: that is the question.
Br. J. Rheumatol.
32:824-826[Abstract/Free Full Text].
|
| 28.
|
Kempsell, K. E.,
C. J. Cox,
M. Hurle,
T. Wong,
S. Wilkie,
E. D. Zanders,
J. S. H. Gaston, and J. S. Crowe.
2000.
Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue.
Infect. Immun.
68:6012-6026[Abstract/Free Full Text].
|
| 29.
|
Kempsell, K. E.,
Y.-E. Ji,
I. C. E. Estrada,
M. J. Colston, and R. A. Cox.
1992.
The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of Mycobacterium tuberculosis and comparison with Mycobacterium leprae precursor rRNA.
J. Gen. Microbiol.
138:1717-1727.
|
| 30.
|
Kitas, G. D.,
M. Salmon,
M. Farr,
S. P. Young, and P. A. Bacon.
1988.
T-cell functional defects in rheumatoid arthritis: intrinsic or extrinsic?
J. Autoimmun.
1:339-351[CrossRef][Medline].
|
| 31.
|
Kogure, T.,
H. Fijinaga,
A. Niizawa,
Y. Shimada,
Y. Itoh,
H. Ochiai, and K. Terasawa.
1999.
Rheumatoid arthritis complicated by Mycobacterium tuberculosis: are there characteristics predisposing to this condition.
J. Clin. Rheumatol.
5:17-21.
|
| 32.
|
Krause, A.,
T. Kamradt, and G. Burmester.
1996.
Potential infectious agents in the induction of arthritides.
Curr. Opin. Rheumatol.
8:203-209[Medline].
|
| 33.
|
Li, S. G.,
A. J. Quayle,
Y. Shen,
J. Kjeldsen-Kragh,
F. Oftung,
R. S. Gupta,
J. B. Natvig, and Ø. T. Førre.
1992.
Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation.
Arthritis Rheum.
35:270-281[Medline].
|
| 34.
|
Lydyard, P. M.,
G. A. Rook,
G. Tsoulfa,
M. Sharif, and M. Smith.
1991.
Is there a role for mycobacteria in the etiopathogenesis of rheumatoid arthritis.
Immunol. Rev.
121:137-154[CrossRef][Medline].
|
| 35.
|
Macfarlane, J. D.,
P. A. Dieppe,
B. G. Rigden, and T. J. Clark.
1978.
Pulmonary and pleural lesions in rheumatoid arthritis.
Br. J. Dis. Chest
72:288-300[Medline].
|
| 36.
|
Maini, R. N.,
C. Q. Chu, and M. Feldmann.
1995.
Aetiopathogenesis of rheumatoid arthritis, p. 25-46.
In
B. Henderson, J. C. W. Edwards, and E. R. Pettipher (ed.), Mechanisms and models in rheumatoid arthritis. Academic Press Ltd., London, England.
|
| 37.
|
Mangan, J. A.,
K. M. Sole,
D. A. Mitchison, and P. D. Butcher.
1997.
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria.
Nucleic Acids Res.
25:675-676[Abstract/Free Full Text].
|
| 38.
|
Maniatis, T.,
E. F. Fritsch, and J. Sambrook.
1982.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 39.
|
Medrano, J. M. M., and J. C. V. Galbete.
1990.
Evidencia morfológica dela presencia de un bacilo en cultivos celulares de membrana sinovial de enfermos de artritis reumatoide.
Rev. Clin. Esp.
187:329-333[Medline].
|
| 40.
|
Meghji, S.,
P. A. White,
S. P. Nair,
K. Reddi,
K. Heron,
B. Henderson,
A. Zaliani,
G. Fossati,
P. Mascagni,
J. F. Hunt,
M. M. Roberts, and A. R. M. Coates.
1997.
Mycobacterium tuberculosis chaperonin 10 stimulates bone resorption: a potential contributory factor in Pott's disease.
J. Exp. Med.
186:1241-1246[Abstract/Free Full Text].
|
| 41.
|
Melief, M. J.,
M. A. Hoijer,
H. C. Van Paassen, and M. P. Hazenberg.
1995.
Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells.
Br. J. Rheumatol.
34:1112-1116[Abstract/Free Full Text].
|
| 42.
|
Mielants, H.,
M. De Vos,
S. Goemaere,
K. Schelstraete,
C. Cuvelier,
K. Goethals,
M. Maertens,
C. Ackerman, and E. M. Veys.
1991.
Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease.
J. Rheumatol.
18:394-400[Medline].
|
| 43.
|
Nilsson, E.,
L. V. von Stedingk, and G. Biberfeld.
1986.
T-cell helper activity and B-cell function of synovial and blood lymphocytes from patients with rheumatoid arthritis or other forms of chronic arthritis.
Scand. J. Immunol.
24:721-728[CrossRef][Medline].
|
| 44.
|
Ottenhoff, T. H.,
P. Torres,
J. T. de las Aguas,
R. Fernandez,
W. van Eden,
R. R. de Vries, and J. L. Stanford.
1986.
Evidence for an HLA-DR4-associated immune-response gene for Mycobacterium tuberculosis. A clue to the pathogenesis of rheumatoid arthritis.
Lancet
2:310-313[CrossRef][Medline].
|
| 45.
|
Palacios-Boix, A. A.,
I. Estrada-G,
M. Joseph Colston, and G. S. Panayi.
1987.
HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects.
J. Immunol.
140:1844-1850[Abstract/Free Full Text].
|
| 46.
|
Panush, R. S., and S. Longley.
1985.
Therapies of potential but unproven benefit, p. 695-709.
In
P. D. Utsinger, N. J. Zvaifler, and G. E. J. B. Erlich (ed.), Rheumatoid arthritis: etiology: diagnosis: management. Lippincott Co., Philadelphia, Pa.
|
| 47.
|
Pettifer, E. R., and S. Blake.
1995.
Antigen-induced arthritis, p. 457-470.
In
B. Henderson, J. C. W. Edwards, and E. R. Pettipher (ed.), Mechanisms and models in rheumatoid arthritis. Academic Press Ltd., London, England.
|
| 48.
|
Pras, E.,
H. R. Schumacher,
D. L. Kastner, and R. L. Wilder.
1996.
Lack of evidence of mycobacteria in synovial tissue from patients with rheumatoid arthritis.
Arthritis Rheum.
39:2080-2081[Medline].
|
| 49.
|
Ragno, S.,
V. R. Winrow,
P. Mascagni,
P. Lucietto,
F. di Pierro,
C. J. Morris, and D. R. Blake.
1996.
A synthetic 10-kDa heat shock protein (hsp 10) from Mycobacterium tuberculosis modulates adjuvant arthritis.
Clin. Exp. Immunol.
103:384-390[CrossRef][Medline].
|
| 50.
|
Relman, D. A.
1999.
The search for unrecognised pathogens.
Science
284:1308-1310[Abstract/Free Full Text].
|
| 51.
|
Res, P. C. M.,
D. Telgt,
J. M. van Laar,
M. O. Pool,
F. C. Breedveld, and R. R. P. de Vries.
1990.
High antigen reactivity in mononuclear cells from sites of chronic inflammation.
Lancet
336:1406-1408[CrossRef][Medline].
|
| 52.
|
Res, P. C.,
C. G. Schaar,
F. C. Breedveld,
W. van Eden,
J. D. van Embden,
I. R. Cohen, and R. R. de Vries.
1988.
Synovial fluid T cell rectivity against 65 kDa heat shock protein of mycobacteria in early chronic arthritis.
Lancet
2:478-480[Medline].
|
| 53.
|
Reynes, J.,
C. Perez,
I. Lamaury,
F. Janbon, and A. Bertrand.
1989.
Bacille Calmette-Guerin adenitis 30 years after immunization in a patient with AIDS.
J. Infect. Dis.
160:727[Medline].
|
| 54.
|
Rich, T.,
U. Gruneberg, and J. Trowsdale.
1998.
Heat shock proteins, HLA-DR and rheumatoid arthritis.
Nat. Med.
4:1210-1211[Medline].
|
| 55.
|
Rook, G.,
P. Lydyard, and J. Stanford.
1990.
Mycobacteria and rheumatoid arthritis.
Arthritis Rheum.
33:431-435[Medline].
|
| 56.
|
Rook, G., and J. McCulloch.
1992.
HLA-DR4, mycobacteria, heat shock proteins and rheumatoid arthritis.
Arthritis Rheum.
35:1409-1412[Medline].
|
| 57.
|
Sawitzke, A. D., and J. R. Ward.
1998.
An infected rheumatoid joint, p. 16.22-16.24.
In
J. H. Klippel, and P. A. Dieppe (ed.), Rheumatology, 2nd ed., vol. 1, Sect. 5. Mosby International, London, England.
|
| 58.
|
Seitz, M.,
I. Napierski, and H. Kirchner.
1988.
Depressed PPD and tetanus toxoid presentation by monocytes to T lymphocytes in patients with rheumatoid arthritis: restoration by interferon gamma.
Rheumatol. Int.
8:189-196[CrossRef][Medline].
|
| 59.
|
Sioud, M.,
J. Kjeldsen-Kragh,
A. J. Quayle,
H. G. Wiker,
D. Sørskaar,
J. B. Natvig, and Ø. Førre.
1991.
Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatois patients and V usage by specific synovial T-cell lines and fresh T cells.
Scand. J. Immunol.
34:803-812[CrossRef][Medline].
|
| 60.
|
Smith, E.,
S. Thybo, and J. Bennedsen.
1992.
Infection with Mycobacterium bovis in a patient with AIDS: a late complication of BCG vaccination.
Scand. J. Infect. Dis.
24:109-110[Medline].
|
| 61.
|
Trentham, D. E., and R. Dynesius-Trentham.
1995.
Collagen-induced arthritis, p. 447-456.
In
B. Henderson, J. C. W. Edwards, and E. R. Pettipher (ed.), Mechanisms and models in rheumatoid Arthritis. Academic Press Ltd., London, England.
|
| 62.
|
Utsinger, P. D.,
N. J. Zvaifler, and S. B. Weiner.
1985.
Etiology, p. 21-48.
In
P. D. Utsinger, N. J. Zvaifler, and G. E. J. B. Erlich (ed.), Rheumatoid arthritis: etiology: diagnosis: management. Lippincott Co., Philadelphia, Pa.
|
| 63.
|
Van der Heijen, I. M.,
B. Wilbrink,
L. M. Schouls,
J. D. van Embden,
F. C. Breedveld, and P. P. Tak.
1999.
Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis.
Rheumatology
38:547-553[Abstract/Free Full Text].
|
| 64.
|
van Deutekom, H.,
Y. M. Smulders,
K. J. Roozendaal, and D. van Soolingen.
1996.
Bacille Calmette-Guerin (BCG) meningitis in an AIDS patient 12 years after vaccination with BCG.
Clin. Infect. Dis.
22:870-871[Medline].
|
| 65.
|
Verwilghen, J.,
V. Corrigall,
R. M. Pope,
R. Rodrigues, and G. S. Panayi.
1993.
Expression and function of CD5 and CD28 in patients with rheumatoid arthritis.
Immunology
80:96-102[Medline].
|
| 66.
|
Wilbrink, B.,
I. M. van der Heijden,
L. M. Schouls,
J. D. A. van Embden,
J. M. W. Hazes,
F. C. Breedveld, and P. P. Tak.
1998.
Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis using polymerase chain reaction with universal 16S ribosomal RNA primers.
Arthritis Rheum.
41:535-543[CrossRef][Medline].
|
| 67.
|
Wilbrink, B.,
J. W. Bilsma,
O. Huber-Bruning,
J. L. Van Roy,
W. Den Otter, and W. van Eden.
1990.
Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion.
J. Rheumatol.
17:532-537[Medline].
|
| 68.
|
Wilkinson, N. Z.,
G. H. Kingsley,
H. W. Jones,
J. Sieper,
J. Braun, and M. E. Ward.
1999.
The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction.
Rheumatology
38:260-266[Abstract/Free Full Text].
|
| 69.
|
Wu, C.-H., and J.-L. Lan.
1992.
Detection of Mycobacterium tuberculosis antigen in synovial fluid of patients with rheumatoid arthritis.
Brit. J. Rheumatol.
31:615-618[Abstract/Free Full Text].
|
| 70.
|
Wu, C.-H.,
K.-C. Jeng, and J.-L. Lan.
1995.
Mycobacterium tuberculosis antigen, interleukin 2 and interleukin 2 inhibitor in patients with rheumatoid arthritis.
Immunol. Investig.
24:957-964[Medline].
|
Infection and Immunity, March 2001, p. 1821-1831, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1821-1831.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yun, Y.-J., Lee, K.-H., Haihua, L., Ryu, Y.-J., Kim, B.-J., Lee, Y.-H., Baek, G.-H., Kim, H.-J., Chung, M.-S., Lee, M.-C., Lee, S.-H., Choi, I.-H., Cho, T.-J., Chang, B.-S., Kook, Y.-H.
(2005). Detection and Identification of Mycobacterium tuberculosis in Joint Biopsy Specimens by rpoB PCR Cloning and Sequencing. J. Clin. Microbiol.
43: 174-178
[Abstract]
[Full Text]